Pediatric Neurotoxicity of Anesthetic Agents: Are We too Worried or too Little?

Rashmi Bhatt1   Puneet Khanna1

1Department of Anaesthesiology, Pain Medicine and Critical Care, AIIMS, New Delhi, India

Address for correspondence Puneet Khanna, MD, E-141, Second Floor, G K II, New Delhi 110 048, India (e-mail: k.punit@yahoo.com).


Abstract

Keywords

► anesthetic agents
► neonates and infants
► neurocognition
► neurotoxicity

The debate on possible neurocognitive adverse effects of anesthetic agents refuses to cease. As evidence builds up, both for and against the debate, a conclusion evades us. More human studies on the subject have now been carried out, and yet we do not have a consensus. In this review, we attempt to relook at the existing evidence, as well as examine some new information as we pursue a greater understanding of this complex matter.

Introduction

Until a few years ago, the only questions that worried parents of children undergoing surgery, would ask were about the risks of surgery. More than the implied safety of the anesthetic procedures, it was the apparent insignificance of their contribution to the risk. Anesthesia was believed to be too simple to pose any significant danger both to the short term as well as long-term outcome. Millions of children undergo various surgical procedures, every year across the world. As anesthesia practice has evolved, we have newer drugs with better safety profiles, and yet much remains unknown about their adverse effects. Probably, one of the most debated controversies of the last decade is the possibility of adverse neurocognitive effects of commonly used anesthetic agents. The fact, that such effects have been associated with agents which have long been in use and remain so today is of much concern as it puts a large number of children at risk. While on the one hand, physicians across the world are attempting to minimize maternal exposure to drugs and environmental factors to prevent adverse foetal neurological outcomes, the likelihood of anesthetic neurotoxicity is worrisome. As is now widely acknowledged that neuronal synaptogenesis continues well into early childhood, the implications of increased anesthetic exposures to paediatric patients could be serious, especially in neonates and infants.11 The data available from animal studies has certainly changed the way we look at paediatric anesthesia.

Most of the preclinical research data come from work on the rodent and primate brain. Not all anesthetic agents have been used in these studies. Ketamine was one of the first drugs to be studied. Its use in dose range of 20–50 mg/kg for up to 24 h demonstrated widespread neuroapoptosis in rat brain.10 Diazepam administration was associated with cell degeneration in parietal cortex and laterodorsal thalamus in the same species.12 These effects were more prominent with the repeated and prolonged administration of the agents. Other agents have been used like ethanol and antiepileptic agents which have a similar mechanism of action.13 To replicate clinical situations, researchers used various combination of anesthetic agents, similar to those in clinical practice, though in much lower doses. The use of midazolam, isoflurane and nitrous oxide, together for 6 h resulted in apoptotic neurodegeneration along with memory and learning impairment in rats.14

What Do We Know?

Agents such as ketamine, benzodiazipines and inhalational agents have been a part of anesthetic practice for decades. It was for the first time in 1999 that Ikonomidou et al. cast a shadow of doubt by bringing to light their observation.10 For the first time, there was concrete evidence of undesirable neurotoxic effects of anesthetic agents on the brain, albeit rodent brain. Although till date we do not have a consensus to the debate, yet the evidence, both for and against the argument is increasing, probably taking us closer to the facts.

DOI https://doi.org/10.1055/s-0037-1618323
ISSN 2348-0548.

Copyright ©2018 Indian Society of Neuroanaesthesiology and Critical Care

License terms
Alarmingly, the use of isoflurane alone for 1 h and at MAC values <1 was also seen to produce significant changes. The use of sevoflurane and propofol is also not entirely safe. Their use in rodents was also seen to result apoptotic neurodegeneration. Most of these effects were observed to occur in the first 1-2 weeks of life in these animals, which was the period of peak synaptic generation activity. Furthermore, these changes could be identified in multiple areas of the brain including, the cortex, thalami, hippocampus basal ganglia as well as the spinal cord. Non-rodent studies carried out in piglets and monkeys have also led to similar derivations, with those on the piglet brain being of particular relevance as it closely resembles the human brain with respect to development and myelination.

The proposed mechanism of this anesthetic neurotoxicity is a reduced synaptic activity due to a reduction in trophic factors. This leads to initiation of the apoptotic pathways in the postsynaptic neurons, through both intrinsic and extrinsic pathways leading to cell death. The anesthesia-induced synaptic suppression is believed to be the cause of decreased synthesis of brain derived neurotrophin factor, thereby promoting cell death. The precise mechanism of suppression of synaptic signalling by anesthetic agents is unknown, but effects on synaptic transmission of glutamate and GABA are believed to be responsible. This is further corroborated by the apoptotic effects observed with use of GABAergic drugs such as midazolam, propofol, thiopentone and volatile anesthetics. The extrinsic pathway of apoptotic initiation is also believed to contribute to anesthetic neurotoxicity, seen with ketamine, propofol and isoflurane, by the suppression of prosurvival extracellular-related kinase signalling. Lithium and dexmedetomidine are believed to be neuroprotective by interfering in this pathway. Several anesthetic agents have been found to exert an anti-inflammatory effect in adults whereas a pro inflammatory effect is seen at a younger age. This is also believed to add to the inflammatory insult caused by surgery and pain. The pattern of neuronal injury also appears to be heterogeneous. The cholinergic neurons appear to be most resistant to neuronal injury, and since anesthesia has been shown to cause cholinergic suppression, it appears to increase the susceptibility of the cells to cell death. Anesthetics induced seizure activity has also been proposed as a mechanism, though no electroencephalogram verification of the same has been seen. Pre-existing hypoxic or ischemic damage to the brain neurons has been observed to increase the vulnerability of neurons to apoptosis. This observation puts neonates with even mild hypoxic injury at increased risk of neurotoxicity, thereby affecting their long-term neurological outcome significantly.

### Table 1: An overview of significant human studies on anesthetic neurotoxicity

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Age at exposure studied</th>
<th>Study design</th>
<th>Outcome and inferences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rozé et al²</td>
<td>2008</td>
<td>&lt;33 wks</td>
<td>Prospective, population based Exposure to sedatives including opioids</td>
<td>No association of prolonged sedation with adverse outcome</td>
</tr>
<tr>
<td>Kalkman et al³</td>
<td>2009</td>
<td>&lt;2 y</td>
<td>Retrospective cohort Exposure to inhalational agents, fentanyl, sufentanil</td>
<td>No confirmation of any effect, underpowered study</td>
</tr>
<tr>
<td>Barrels et al⁴</td>
<td>2009</td>
<td>&lt;3 y</td>
<td>Monozygotic concordant-discordant twin study Early versus late exposure compared</td>
<td>No observed differences between exposed and unexposed twin</td>
</tr>
<tr>
<td>Guerra et al⁵</td>
<td>2011</td>
<td>&lt;6 wks</td>
<td>Prospective postoperative follow-up in cardiac surgery Exposure to inhalational agents, opioids, benzodiazepines, ketamine</td>
<td>No association between anesthetic exposure and neurodevelopment</td>
</tr>
<tr>
<td>DiMaggio et al⁶</td>
<td>2011</td>
<td>&lt;3 y</td>
<td>Retrospective sibling birth cohort design</td>
<td>Risk of diagnosis higher in exposed group but no causal connection</td>
</tr>
<tr>
<td>Flick et al⁷</td>
<td>2011</td>
<td>&lt;2 y</td>
<td>Retrospective matched cohort study Compared single versus multiple anesthesia exposures to halothane and nitrous oxide</td>
<td>Increased risk for a learning disability with multiple exposures</td>
</tr>
<tr>
<td>Sun et al⁸</td>
<td>2012</td>
<td>&lt;3 y</td>
<td>Sibling-matched cohort study Exposure to inhaled agents</td>
<td>No risk found with single exposure in healthy children</td>
</tr>
<tr>
<td>Yazar et al⁹</td>
<td>2016</td>
<td>&lt;3 y</td>
<td>Cohort study</td>
<td>No association between anesthesia exposure and myopia, reduced visual acuity or retinal nerve thinning</td>
</tr>
</tbody>
</table>
Do We Know Enough?

Despite concrete evidence available from preclinical studies, its extrapolation to and interpretation in human subjects has proved to be far more difficult. A prospective, controlled randomized trial would be a litmus test for the proposed theories and observations of the animal studies. Herein, lies the difficulty: both ethical and practical. The application of animal research to human subjects is rarely straightforward, but the study of anesthetic neurotoxicity has been one of the biggest challenges of recent times. The ethical challenge lies in drawing up the control group, the practical in follow-up. A true control would be a child who would not receive anesthesia for surgery which is an unacceptable proposition. Neither would it be ethical to prevent this child from undergoing surgery. No procedure in the paediatric population is truly an elective one. Any surgery deferred in the present carries consequences if postponed indefinitely. Many surgeries like hernia repair can definitely be scheduled beyond the most active synaptogenetic phase, but do require eventual correction. Which brings us to the next challenging aspect. Despite several hypothesis, it is not really known as to what age the human brain remains susceptible to neurotoxic effects of anesthetic agents. The vulnerable period in animal brain does not correlate accurately with human neurodevelopment. What is known, by limited research and consensus is that the intrauterine period as well as early childhood is the most likely to be affected. Most anesthetists would like to defer procedures like hernia repair to beyond 3 years of age, but dilemma arises for procedures whose correction bears importance on neurological as well as psychological correction. These include hypospadias repair, cleft lip and palate surgery, cochlear implant, etc.

Another problem arises with respect to the doses of the anesthetic drugs used in animal studies. It is well-known that dose requirements of these drugs in animal groups is much higher, varying even across the species. Since the clinically used doses are much lower, the safety margin is difficult to estimate, and the safety can never be established entirely. Although repeated exposure to anesthetic drugs is a definite risk factor but precisely how much is too much cannot be determined.

A prospective study entails prolonged periods of follow-up for evaluation with no well-defined end points. It is difficult to know at what age the neurobehavioural changes will start manifesting, and beyond what age can we expect no new changes, to allow the end of follow-up. Hence, the exact period of observation is difficult to draw up. This makes these studies long, tedious and likely to miss out on causative association. The PANDA and the GAS studies are two early significant prospective studies whose observations were made available.

Hence, the alternative remains retrospective observational cohort studies, many of which have in fact been carried out, though with drawbacks of their own. The biggest problem is of the confounding factors. Neurobehavioural development is a complex phenomenon which continues to baffle neuroscientists. It incorporates a complex interplay of socioeconomic, environmental and genetic factors which can alter behaviour and cognition, at multiple stages in life. Most epidemiologists now believe adolescence to be a just as important a phase in neurodevelopment as early childhood. The effect of these factors can never be entirely eliminated, even in cohorts of sibling pairs or twin pairs. A Dutch twin study carried out in 2009 by Bartels et al. failed to demonstrate any difference in school performance among pair of twins receiving anesthesia exposure selectively. Similarly, the PANDA study using sibling pairs with differential anesthesia exposure failed to establish any difference in the intelligence quotient (IQ) scores of these pairs. Glatz et al. in 2016, concluded from a Swedish national cohort that surgical and anesthetic exposure before 4 years of age bore minimal effect on cognitive performance. Despite several children receiving multiple anesthetic exposures, the academic achievements were more significantly affected by other factors, especially environmental.

Large cohort studies can adjust for some of the confounding factors, but some unknown factors always exist, which preclude the establishment of causation and association. In addition, factors like variable frequency and duration of anesthetic exposures also make it difficult to draw clinically relevant conclusions. Some of the anesthetic agents such as midazolam and ketamine find use in the paediatric intensive care units, where their prolonged use could be a matter of concern. On the one hand, a Cochrane review has found some evidence of an adverse short-term outcome with a prolonged midazolam infusion use in neonates, on the other hand, the EPPHAGE cohort study failed to establish any association between sedation exposure and outcome.

At the core of our understanding of neurobehavioural changes lies the use of assessment tools such as IQ score, mental scores and assessment methods for developmental delay. These are difficult to apply and interpret in very young children and can be reliably used only in the school going population. Hence, subtle changes in behaviour at early age may, in fact, be missed. Conversely, broad investigational batteries may, in fact, find associations, purely by chance and lead to fallacious results. All these factors result in even clinical studies being inconclusive.

So Is it all Bad?

So what does all the discussion and contention lead us to. We definitely do not have a conclusion, neither can we refute the evidence before us nor can we confirm it. Enough has been stated about the noxious effects of the anesthetic agents on neurodevelopment. We must however not overlook the accumulating data in favour of several anesthetic agents which have a potential to protect against anesthetic neurotoxicity. Of much interest is the class of alpha-2 adrenergic agonists which includes clonidine and dexmedetomidine. These have been observed to reduce anesthetic induced neuroapoptosis and resultant behavioural changes. Both of these drugs have not been found to possess any apoptotic effects by themselves. Another drug to have captured...
interest is xenon. In itself, it is minimally toxic but is effective against isoflurane-induced apoptosis. Being an N-methyl-D-aspartate antagonist, it is similar to ketamine in its mechanism of action but does not share its neurotoxic profile. It cost and availability constraints do limit its use, but the neuroprotection is promising.

Free radical scavengers such as melatonin and estradiol, which are also anti-inflammatory, have also been found to prevent anesthetic and anti-epileptic-induced neurotoxicity. Other agents which are extensively being examined for their neuroprotective properties are lithium, hypothermia, L-carnitine, bumetanide and erythropoietin.

Neonatal pain, induced by surgery, is known to induce long-term behavioural effects in animals and humans, emphasising the need for adequate analgesia in the perinatal period. The impact of surgery, in addition to anesthesia, on perinatal brain injury also requires further investigation as inflammatory stimulation could exacerbate pre-existing hypoxic-ischemic injury. Surgery induces significant pain and inflammation that might worsen the toxic injury of hypoxia-ischemia by augmenting neuronal activity. In children undergoing surgery, anesthesia and analgesia serve to partly reduce adverse metabolic, immunological and humoral responses of surgery and pain. So, in fact, these protective effects can improve outcome in critically ill neonates and infants.

Regional anesthesia is an important component of anesthetic plan, even in the pediatric population. The feasibility of awake regional anesthesia in neonates, especially preterm neonates, offers dual advantage of avoiding general anesthesia as well as postoperative apnoeic episodes. However, it requires much expertise and finds limited use in abdominal and thoracic procedures.

The Final Word

There are numerous questions and controversies that remain unanswered as the clinical relevance of the enormous preclinical evidence of neurotoxicity continues to evade us. SmartTots is a collaborative effort of the International Anesthesia Research Society, the U.S. Food and Drug Administration and many others who are working to make anesthesia safer for infants and children. It is a multi-year collaborative effort designed to research the subject as well as provide information to those who seek it. It remains to be seen whether neuroprotective agents, effective in rodents, can provide clinical protection, and more importantly is anesthesia as detrimental as it appears to be? We are a long way from clinical trials of these apparent neuroprotective agents. The need for more prospective studies and translational research cannot be emphasised enough. The search for better evaluation of neuronal injury has already led us to biomarkers and micro-posision emission tomography imaging techniques to accurately detect sensitive and quantitative three dimensional molecular information from the brain. For now, it seems agreeable and rational to minimize anesthetic exposure for procedures which cannot be delayed and to ensure the safest standards of care.

Funding
None.

Conflict of interest
None.

References